Paraoxonases. Ancient Substrate Hunters and Their Evolving Role in Ischemic Heart Disease

Advances in Clinical Chemistry

Volumn 59, Issue , 2013, Pages 65-100

  Martinelli, Nicola ^a   Consoli, Letizia ^a   Girelli, Domenico ^a   Grison, Elisa ^a   Corrocher, Roberto ^a   Olivieri, Oliviero ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84870987555     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-405211-6.00003-6     Document Type: Chapter

References (202)

1. Mazur A., Bodanski O. The mechanism of in vitro and in vivo inhibition of cholinesterase activity by diisopropyl fluorophosphate. J. Biol. Chem. 1946, 163:261-276.
2. Schrader G. Organische phosphor Verbindungen als neuartige Insektizide. Angew. Chem. 1950, 62:471-473.
3. Aldrige W.N. The inhibition of erythrocyte cholinesterase by tri-esters of phosphoric acid. III. The nature of the inhibitory process. Biochem. J. 1953, 54:442-448.
4. James R.W. A long and winding road: defining the biological role and clinical importance of paraoxonases. Clin. Chem. Lab. Med. 2006, 44:1052-1059.
5. Eckerson H.W., Romson J., Wyte C., La Du B.N. The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am. J. Hum. Genet. 1983, 35:214-227.
6. Eckerson H.W., Wyte C.M., La Du B.N. The human serum paraoxonase/arylesterase polymorphism. Am. J. Hum. Genet. 1983, 35:1126-1138.
7. Humbert R., Adler D.A., Disteche C.M., Hassett C., Omiecinski C.J., Furlong C.E. The molecular basis of the human serum paraoxonase activity polymorphism. Nat. Genet. 1993, 3:73-76.
8. Adkins S., Gan K.N., Mody M., La Du B.N. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am. J. Hum. Genet. 1993, 52:598-608.
9. Gaidukov L., Rosenblat M., Aviram M., Tawfik D.S. The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux. J. Lipid Res. 2006, 47:2492-2502.
10. Garin M.C., James R.W., Dussoix P., et al. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J. Clin. Invest. 1997, 99:62-66.
11. Brophy V.H., Jampsa R.L., Clendenning J.B., McKinstry L.A., Jarvik G.P., Furlong C.E. Effects of 5′ regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am. J. Hum. Genet. 2001, 68:1428-1436.
12. Brophy V.H., Hastings M.D., Clendenning J.B., Richter R.J., Jarvik G.P., Furlong C.E. Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics 2001, 11:77-84.
13. Mackness M.I., Arrol S., Durrington P.N. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 1991, 286:152-154.
14. McElveen J., Mackness M.I., Colley C.M., Peard T., Warner S., Walker C.H. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin. Chem. 1986, 32:671-673.
15. Ruiz J., Blanché H., James R.W., et al. Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 1995, 346:869-872.
16. Serrato M., Marian A.J. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J. Clin. Invest. 1995, 96:3005-3008.
17. Shih D.M., Gu L., Xia Y.R., et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998, 394:284-287.
18. Primo-Parmo S.L., Sorenson R.C., Teiber J., La Du B.N. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996, 33:498-507.
19. Hassett C., Richter R.J., Humbert R., et al. Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. Biochemistry 1991, 30:10141-10149.
20. Reddy S.T., Wadleigh D.J., Grijalva V., et al. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler. Thromb. Vasc. Biol. 2001, 21:542-547.
21. Shih D.M., Lusis A.J. The roles of PON1 and PON2 in cardiovascular disease and innate immunity. Curr. Opin. Lipidol. 2009, 20:288-292.
22. Camps J., Marsillach J., Joven J. The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit. Rev. Clin. Lab. Sci. 2009, 46:83-106.
23. Draganov D.I., Stetson P.L., Watson C.E., Billecke S.S., La Du B.N. Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J. Biol. Chem. 2000, 275:33435-33442.
24. Ng C.J., Wadleigh D.J., Gangopadhyay A., et al. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J. Biol. Chem. 2001, 276:44444-44449.
25. Horke S., Witte I., Wilgenbus P., Krüger M., Strand D., Förstermann U. Paraoxonase-2 reduces oxidative stress in vascular cells and decreases endoplasmic reticulum stress-induced caspase activation. Circulation 2007, 115:2055-2064.
26. Furlong C.E. Genetic variability in the cytochrome P450-paraoxonase 1 (PON1) pathway for detoxication of organophosphorus compounds. J. Biochem. Mol. Toxicol. 2007, 21:197-205.
27. Khersonsky O., Roodveldt C., Tawfik D.S. Enzyme promiscuity: evolutionary and mechanistic aspects. Curr. Opin. Chem. Biol. 2006, 10:498-508.
28. Draganov D.I., Teiber J.F., Speelman A., Osawa Y., Sunahara R., La Du B.N. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J. Lipid Res. 2005, 46:1239-1247.
29. Ozer E.A., Pezzulo A., Shih D.M., et al. Human and murine paraoxonase 1 are host modulators of Pseudomonas aeruginosa quorum-sensing. FEMS Microbiol. Lett. 2005, 253:29-37.
30. Bouman H.J., Schömig E., van Werkum J.W., et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat. Med. 2011, 17:110-116.
31. Marsillach J., Mackness B., Mackness M., et al. Immunohistochemical analysis of paraoxonases-1, 2, and 3 expression in normal mouse tissues. Free Radic. Biol. Med. 2008, 45:146-157.
32. Harel M., Aharoni A., Gaidukov L., et al. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat. Struct. Mol. Biol. 2004, 11:412-419.
33. Aharoni A., Gaidukov L., Khersonsky O., McQ Gould S., Roodveldt C., Tawfik D.S. The 'evolvability' of promiscuous protein functions. Nat. Genet. 2005, 37:73-76.
34. Aharoni A., Gaidukov L., Yagur S., Toker L., Silman I., Tawfik D.S. Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization. Proc. Natl. Acad. Sci. USA. 2004, 101:482-487.
35. Khersonsky O., Tawfik D.S. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 2005, 44:6371-6382.
36. Khersonsky O., Tawfik D.S. The histidine 115-histidine 134 dyad mediates the lactonase activity of mammalian serum paraoxonases. J. Biol. Chem. 2006, 281:7649-7656.
37. James R.W., Blatter Garin M.C., Calabresi L., et al. Modulated serum activities and concentrations of paraoxonase in high density lipoprotein deficiency states. Atherosclerosis 1998, 139:77-82.
38. Blatter M.C., James R.W., Messmer S., Barja F., Pometta D. Identification of a distinct human high density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur. J. Biochem. 1993, 211:871-879.
39. Lamarche B., Moorjani S., Cantin B., Dagenais G.R., Lupien P.J., Després J.P. Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. Arterioscler. Thromb. Vasc. Biol. 1997, 17:1098-1105.
40. Williams P.T., Feldman D.E. Prospective study of coronary heart disease vs. HDL2, HDL3, and other lipoproteins in Gofman's Livermore Cohort. Atherosclerosis 2011, 214:196-202.
41. Vaisar T., Pennathur S., Green P.S., et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J. Clin. Invest. 2007, 117:746-756.
42. Heinecke J.W. The HDL proteome: a marker-and perhaps mediator-of coronary artery disease. J. Lipid Res. 2009, 50(Suppl.):S167-S171.
43. Kelso G.J., Stuart W.D., Richter R.J., Furlong C.E., Jordan-Starck T.C., Harmony J.A. Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry 1994, 33:832-839.
44. Deakin S., Leviev I., Gomaraschi M., Calabresi L., Franceschini G., James R.W. Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. J. Biol. Chem. 2002, 277:4301-4308.
45. Deakin S.P., James R.W. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin. Sci. (Lond.) 2004, 107:435-447.
46. Sorenson R.C., Bisgaier C.L., Aviram M., Hsu C., Billecke S., La Du B.N. Human serum paraoxonase/arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity. Arterioscler. Thromb. Vasc. Biol. 1999, 19:2214-2225.
47. Rothem L., Hartman C., Dahan A., Lachter J., Eliakim R., Shamir R. Paraoxonases are associated with intestinal inflammatory diseases and intracellularly localized to the endoplasmic reticulum. Free Radic. Biol. Med. 2007, 43:730-739.
48. Witte I., Foerstermann U., Devarajan A., Reddy S.T., Horke S. Protectors or traitors: the roles of PON2 and PON3 in atherosclerosis and cancer. J. Lipids 2012, 2012:342806.
49. Khersonsky O., Rosenblat M., Toker L., et al. Directed evolution of serum paraoxonase PON3 by family shuffling and ancestor/consensus mutagenesis, and its biochemical characterization. Biochemistry 2009, 48:6644-6654.
50. Aragonès G., Guardiola M., Barreda M., et al. Measurement of serum PON-3 concentration: method evaluation, reference values, and influence of genotypes in a population-based study. J. Lipid Res. 2011, 52:1055-1061.
51. Parthasarathy S., Barnett J., Fong L.G. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim. Biophys. Acta 1990, 1044:275-283.
52. Navab M., Ananthramaiah G.M., Reddy S.T., et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J. Lipid Res. 2004, 45:993-1007.
53. Navab M., Hama S.Y., Anantharamaiah G.M., et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J. Lipid Res. 2000, 41:1495-1508.
54. Navab M., Reddy S.T., Van Lenten B.J., Anantharamaiah G.M., Fogelman A.M. The role of dysfunctional HDL in atherosclerosis. J. Lipid Res. 2009, 50(Suppl.):S145-S149.
55. Cockerill G.W., Rye K.A., Gamble J.R., Vadas M.A., Barter P.J. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler. Thromb. Vasc. Biol. 1995, 15:1987-1994.
56. Calabresi L., Gomaraschi M., Villa B., Omoboni L., Dmitrieff C., Franceschini G. Elevated soluble cellular adhesion molecules in subjects with low HDL-cholesterol. Arterioscler. Thromb. Vasc. Biol. 2002, 22:656-661.
57. Cockerill G.W., Huehns T.Y., Weerasinghe A., et al. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E selectin in an in vivo model of acute inflammation. Circulation 2001, 103:108-112.
58. Kalantar-Zadeh K., Kopple J.D., Kamranpour N., Fogelman A.M., Navab M. HDL-inflammatory index correlates with poor outcome in hemodialysis patients. Kidney Int. 2007, 72:1149-1156.
59. Watson A.D., Berliner J.A., Hama S.Y., et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 1995, 96:2882-2891.
60. Mackness M.I., Arrol S., Abbott C., Durrington P.N. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993, 104:129-135.
61. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parmo S.L., La Du B.N. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Invest. 1998, 101:1581-1590.
62. Aviram M., Billecke S., Sorenson R., et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler. Thromb. Vasc. Biol. 1998, 18:1617-1624.
63. Jaouad L., de Guise C., Berrougui H., et al. Age-related decrease in high-density lipoproteins antioxidant activity is due to an alteration in the PON1's free sulfhydryl groups. Atherosclerosis 2006, 185:191-200.
64. Ross R. Atherosclerosis an inflammatory disease. N. Engl. J. Med. 1999, 340:115-126.
65. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
66. Hansson G.K., Hermansson A. The immune system in atherosclerosis. Nat. Immunol. 2011, 12:204-212.
67. Mackness B., Hine D., Liu Y., Mastorikou M., Mackness M. Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem. Biophys. Res. Commun. 2004, 318:680-683.
68. Besler C., Heinrich K., Rohrer L., et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J. Clin. Invest. 2011, 121:2693-2708.
69. Mineo C., Shaul P.W. PON-dering differences in HDL function in coronary artery disease. J. Clin. Invest. 2011, 121:2545-2548.
70. Aviram M., Rosenblat M., Billecke S., et al. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic. Biol. Med. 1999, 26:892-904.
71. Hansson G.K. Atherosclerosis-an immune disease: the Anitschkov Lecture 2007. Atherosclerosis 2009, 202:2-10.
72. Rozenberg O., Rosenblat M., Coleman R., Shih D.M., Aviram M. Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic. Biol. Med. 2003, 34:774-784.
73. Rosenblat M., Gaidukov L., Khersonsky O., et al. The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J. Biol. Chem. 2006, 281:7657-7665.
74. Rosenblat M., Vaya J., Shih D., Aviram M. Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholine. Atherosclerosis 2005, 179:69-77.
75. James R.W., Brulhart-Meynet M.C., Singh A.K., et al. The scavenger receptor class B, type I is a primary determinant of paraoxonase-1 association with high-density lipoproteins. Arterioscler. Thromb. Vasc. Biol. 2010, 30:2121-2127.
76. Refsum H., Ueland P.M., Nygård O., Vollset S.E. Homocysteine and cardiovascular disease. Annu. Rev. Med. 1998, 49:31-62.
77. McCully K.S. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am. J. Pathol. 1969, 56:111-128.
78. Nygard O., Nordrehaug J.E., Refsum H., Ueland P.M., Farstad M., Vollset S.E. Plasma homocysteine levels and mortality in patients with coronary artery disease. N. Engl. J. Med. 1997, 337:230-236.
79. Girelli D., Martinelli N., Olivieri O., et al. Hyperhomocysteinemia and mortality after coronary artery bypass grafting. PLoS One 2006, 1:e83.
80. Bonaa K.H., Njølstad I., Ueland P.M., et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N. Engl. J. Med. 2006, 354:1578-1588.
81. Lonn E., Yusuf S., Arnold M.J., et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N. Engl. J. Med. 2006, 354:1567-1577.
82. Loscalzo J. Homocysteine trials-clear outcomes for complex reasons. N. Engl. J. Med. 2006, 354:1629-1632.
83. Welch G.N., Loscalzo J. Homocysteine and atherothrombosis. N. Engl. J. Med. 1998, 338:1042-1050.
84. Jakubowski H. Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J. 1999, 13:2277-2283.
85. Undas A., Perła J., Lacinski M., Trzeciak W., Kaźmierski R., Jakubowski H. Autoantibodies against N-homocysteinylated proteins in humans: implications for atherosclerosis. Stroke 2004, 35:1299-1304.
86. Sauls D.L., Lockhart E., Warren M.E., Lenkowski A., Wilhelm S.E., Hoffman M. Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia. Biochemistry 2006, 45:2480-2487.
87. Jakubowski H. The pathophysiological hypothesis of homocysteine thiolactone-mediated vascular disease. J. Physiol. Pharmacol. 2008, 59(Suppl. 9):155-167.
88. Jakubowski H. The role of paraoxonase 1 in the detoxification of homocysteine thiolactone. Adv. Exp. Med. Biol. 2010, 660:113-127.
89. Jakubowski H., Ambrosius W.T., Pratt J.H. Genetic determinants of homocysteine thiolactonase activity in humans: implications for atherosclerosis. FEBS Lett. 2001, 491:35-39.
90. Lacinski M., Skorupski W., Cieslinski A., Sokolowska J., Trzeciak W.H., Jakubowski H. Determinants of homocysteine-thiolactonase activity of the paraoxonase-1 (PON1) protein in humans. Cell. Mol. Biol. (Noisy-le-Grand) 2004, 50:885-893.
91. Perla-Kaján J., Jakubowski H. Paraoxonase 1 protects against protein N-homocysteinylation in humans. FASEB J. 2010, 24:931-936.
92. Teiber J.F., Horke S., Haines D.C., et al. Dominant role of paraoxonases in inactivation of the Pseudomonas aeruginosa quorum-sensing signal N-(3-oxododecanoyl)-L-homoserine lactone. Infect. Immun. 2008, 76:2512-2519.
93. Stoltz D.A., Ozer E.A., Ng C.J., et al. Paraoxonase-2 deficiency enhances Pseudomonas aeruginosa quorum sensing in murine tracheal epithelia. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007, 292:L852-L860.
94. Stoltz D.A., Ozer E.A., Taft P.J., et al. Drosophila are protected from Pseudomonas aeruginosa lethality by transgenic expression of paraoxonase-1. J. Clin. Invest. 2008, 118:3123-3131.
95. Saikku P., Lei M., Mattila K., et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988, 2:983-986.
96. Danesh J., Collins R., Peto R. Chronic infections and coronary heart disease: is there a link?. Lancet 1997, 350:430-436.
97. Wang Z., Klipfell E., Bennett B.J., et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011, 472:57-63.
98. Sibbing D., Koch W., Massberg S., et al. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur. Heart J. 2011, 32:1605-1613.
99. Trenk D., Hochholzer W., Fromm M.F., et al. Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement. Circ. Cardiovasc. Genet. 2011, 4:429-436.
100. Fontana P., James R., Barazer I., et al. Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study. J. Thromb. Haemost. 2011, 9:1664-1666.
101. Rideg O., Komócsi A., Magyarlaki T., et al. Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention. Pharmacogenomics 2011, 12:1269-1280.
102. Dansette P.M., Rosi J., Bertho G., Mansuy D. Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer. Chem. Res. Toxicol. 2012, 25:348-356.
103. Gong I.Y., Crown N., Suen C.M., et al. Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response. Eur. Heart J. 2012, 27 February [Epub ahead of print].
104. Reny J.L., Combescure C., Daali Y., Fontana P., PON1 Meta-Analysis Group Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis. J. Thromb. Haemost. 2012, 10:1242-1251.
105. Fortunato G., Di Taranto M.D., Bracale U.M., et al. Decreased paraoxonase-2 expression in human carotids during the progression of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2008, 28:594-600.
106. Rosenblat M., Coleman R., Reddy S.T., Aviram M. Paraoxonase 2 attenuates macrophage triglyceride accumulation via inhibition of diacylglycerol acyltransferase 1. J. Lipid Res. 2009, 50:870-879.
107. Devarajan A., Bourquard N., Hama S., et al. Paraoxonase 2 deficiency alters mitochondrial function and exacerbates the development of atherosclerosis. Antioxid. Redox Signal. 2011, 14:341-351.
108. Witte I., Altenhöfer S., Wilgenbus P., et al. Beyond reduction of atherosclerosis: PON2 provides apoptosis resistance and stabilizes tumor cells. Cell Death Dis. 2011, 2:e112.
109. Altenhöfer S., Witte I., Teiber J.F., et al. One enzyme, two functions: PON2 prevents mitochondrial superoxide formation and apoptosis independent from its lactonase activity. J. Biol. Chem. 2010, 285:24398-24403.
110. Shih D.M., Xia Y.R., Wang X.P., et al. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J. Biol. Chem. 2000, 275:17527-17535.
111. Tward A., Xia Y.R., Wang X.P., et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002, 106:484-490.
112. Mackness B., Quarck R., Verreth W., Mackness M., Holvoet P. Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 2006, 26:1545-1550.
113. Ng C.J., Bourquard N., Grijalva V., et al. Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoprotein-B-containing lipoproteins: anti-atherogenic role for paraoxonase-2. J. Biol. Chem. 2006, 281:29491-29500.
114. Ng C.J., Hama S.Y., Bourquard N., Navab M., Reddy S.T. Adenovirus mediated expression of human paraoxonase 2 protects against the development of atherosclerosis in apolipoprotein E-deficient mice. Mol. Genet. Metab. 2006, 89:368-373.
115. Bourquard N., Ng C.J., Reddy S.T. Impaired hepatic insulin signalling in PON2-deficient mice: a novel role for the PON2/apoE axis on the macrophage inflammatory response. Biochem. J. 2011, 436:91-100.
116. Shih D.M., Xia Y.R., Wang X.P., et al. Decreased obesity and atherosclerosis in human paraoxonase 3 transgenic mice. Circ. Res. 2007, 100:1200-1207.
117. Jarvik G.P., Rozek L.S., Brophy V.H., et al. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler. Thromb. Vasc. Biol. 2000, 20:2441-2447.
118. Mackness B., Davies G.K., Turkie W., et al. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype?. Arterioscler. Thromb. Vasc. Biol. 2001, 21:1451-1457.
119. Jarvik G.P., Hatsukami T.S., Carlson C., et al. Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. Arterioscler. Thromb. Vasc. Biol. 2003, 23:1465-1471.
120. Mackness B., Durrington P., McElduff P., et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 2003, 107:2775-2779.
121. Uzun H., Karter Y., Aydin S., et al. Oxidative stress in white coat hypertension; role of paraoxonase. J. Hum. Hypertens. 2004, 18:523-528.
122. Abbott C.A., Mackness M.I., Kumar S., Boulton A.J., Durrington P.N. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler. Thromb. Vasc. Biol. 1995, 15:1812-1818.
123. Sakai T., Matsuura B., Onji M. Serum paraoxonase activity and genotype distribution in Japanese patients with diabetes mellitus. Intern. Med. 1998, 37:581-584.
124. Boemi M., Leviev I., Sirolla C., Pieri C., Marra M., James R.W. Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation. Atherosclerosis 2001, 155:229-235.
125. Sentí M., Tomás M., Fitó M., et al. Antioxidant paraoxonase 1 activity in the metabolic syndrome. J. Clin. Endocrinol. Metab. 2003, 88:5422-5426.
126. Blatter Garin M.C., Moren X., James R.W. Paraoxonase-1 and serum concentrations of HDL-cholesterol and apoA-I. J. Lipid Res. 2006, 47:515-520.
127. Mackness M.I., Harty D., Bhatnagar D., Winocour P.H., Arrol S., Ishola M., Durrington P.N. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991, 86:193-199.
128. Navab M., Hama-Levy S., Van Lenten B.J., et al. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J. Clin. Invest. 1997, 99:2005-2019.
129. Podrez E.A. Anti-oxidant properties of high-density lipoprotein and atherosclerosis. Clin. Exp. Pharmacol. Physiol. 2010, 37:719-725.
130. von Eckardstein A. Implications of torcetrapib failure for the future of HDL therapy: is HDL-cholesterol the right target?. Expert Rev. Cardiovasc. Ther. 2010, 8:345-358.
131. Bhattacharyya T., Nicholls S.J., Topol E.J., et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008, 299:1265-1276.
132. Richter R.J., Jarvik G.P., Furlong C.E. Determination of paraoxonase 1 status without the use of toxic organophosphate substrates. Circ. Cardiovasc. Genet. 2008, 1:147-152.
133. Loscalzo J. Paraoxonase and coronary heart disease risk: language misleads, linkage misinforms, function clarifies. Circ. Cardiovasc. Genet. 2008, 1:79-80.
134. Gaidukov L., Tawfik D.S. The development of human sera tests for HDL-bound serum PON1 and its lipolactonase activity. J. Lipid Res. 2007, 48:1637-1646.
135. Martinelli N., Girelli D., Olivieri O., et al. Novel serum paraoxonase activity assays are associated with coronary artery disease. Clin. Chem. Lab. Med. 2009, 47:432-440.
136. Domagała T.B., Łacinski M., Trzeciak W.H., Mackness B., Mackness M.I., Jakubowski H. The correlation of homocysteine-thiolactonase activity of the paraoxonase (PON1) protein with coronary heart disease status. Cell. Mol. Biol. (Noisy-le-Grand) 2006, 52:4-10.
137. Vekic J., Kotur-Stevuljevic J., Jelic-Ivanovic Z., et al. Association of oxidative stress and PON1 with LDL and HDL particle size in middle-aged subjects. Eur. J. Clin. Invest. 2007, 37:715-723.
138. Costa L.G., Cole T.B., Jarvik G.P., Furlong C.E. Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu. Rev. Med. 2003, 54:371-392.
139. Costa L.G., Giordano G., Furlong C.E. Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on. Biochem. Pharmacol. 2011, 81:337-344.
140. Mackness B., Mackness M.I., Arrol S., Turkie W., Durrington P.N. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett. 1998, 423:57-60.
141. Mackness B., Durrington P.N., Mackness M.I. Polymorphisms of paraoxonase genes and low-density lipoprotein lipid peroxidation. Lancet 1999, 353:468-469.
142. Wheeler J.G., Keavney B.D., Watkins H., Collins R., Danesh J. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 2004, 363:689-695.
143. Wang M., Lang X., Zou L., Huang S., Xu Z. Four genetic polymorphisms of paraoxonase gene and risk of coronary heart disease: a meta-analysis based on 88 case-control studies. Atherosclerosis 2011, 214:377-385.
144. Playfer J.R., Eze L.C., Bullen M.F., Evans D.A. Genetic polymorphism and interethnic variability of plasma paroxonase activity. J. Med. Genet. 1976, 13:337-342.
145. Richter R.J., Furlong C.E. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 1999, 9:745-753.
146. Regieli J.J., Jukema J.W., Doevendans P.A., et al. Paraoxonase variants relate to 10-year risk in coronary artery disease: impact of a high-density lipoprotein-bound antioxidant in secondary prevention. J. Am. Coll. Cardiol. 2009, 54:1238-1245.
147. Aubó C., Sentí M., Marrugat J., et al. Risk of myocardial infarction associated with Gln/Arg 192 polymorphism in the human paraoxonase gene and diabetes mellitus. The REGICOR Investigators. Eur. Heart J. 2000, 21:33-38.
148. Martinelli N., Girelli D., Olivieri O., et al. Interaction between metabolic syndrome and PON1 polymorphisms as a determinant of the risk of coronary artery disease. Clin. Exp. Med. 2005, 5:20-30.
149. Balcerzyk A., Zak I., Krauze J. Synergistic effects between Q192R polymorphism of paraoxonase 1 gene and some conventional risk factors in premature coronary artery disease. Arch. Med. Res. 2007, 38:545-550.
150. Malin R., Loimaala A., Nenonen A., et al. Relationship between high-density lipoprotein paraoxonase gene M/L55 polymorphism and carotid atherosclerosis differs in smoking and nonsmoking men. Metabolism 2001, 50:1095-1101.
151. Martinelli N., Girelli D., Olivieri O., et al. Interaction between smoking and PON2 Ser311Cys polymorphism as a determinant of the risk of myocardial infarction. Eur. J. Clin. Invest. 2004, 34:14-20.
152. Chen Q., Reis S.E., Kammerer C.M., et al. Association between the severity of angiographic coronary artery disease and paraoxonase gene polymorphisms in the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) study. Am. J. Hum. Genet. 2003, 72:13-22.
153. Leus F.R., Zwart M., Kastelein J.J., Voorbij H.A. PON2 gene variants are associated with clinical manifestations of cardiovascular disease in familial hypercholesterolemia patients. Atherosclerosis 2001, 154:641-649.
154. Shi J., Zhang S., Tang M., et al. Possible association between Cys311Ser polymorphism of paraoxonase 2 gene and late-onset Alzheimer's disease in Chinese. Brain Res. Mol. Brain Res. 2004, 120:201-204.
155. Slowik A., Wloch D., Szermer P., et al. Paraoxonase 2 gene C311S polymorphism is associated with a risk of large vessel disease stroke in a Polish population. Cerebrovasc. Dis. 2007, 23:395-400.
156. Wang Y., Luk A.O., Ma R.C., et al. Independent predictive roles of eotaxin Ala23Thr, paraoxonase 2 Ser311Cys and beta-adrenergic receptor Trp64Arg polymorphisms on cardiac disease in Type 2 Diabetes-an 8-year prospective cohort analysis of 1297 patients. Diabet. Med. 2010, 27:376-383.
157. Stoltz D.A., Ozer E.A., Recker T.J., et al. A common mutation in paraoxonase-2 results in impaired lactonase activity. J. Biol. Chem. 2009, 284:35564-35571.
158. Schunkert H., König I.R., Kathiresan S., et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat. Genet. 2011, 43:333-338.
159. Deakin S., Leviev I., Guernier S., James R.W. Statin modulates expression of the PON1 gene and increases serum paraoxonase. A role for sterol regulatory element-binding protein-2. Arterioscler. Thromb. Vasc. Biol. 2003, 23:2083-2089.
160. Mirdamadi H.Z., Sztanek F., Derdak Z., Seres I., Harangi M., Paragh G. The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters. Br. J. Clin. Pharmacol. 2008, 66:366-373.
161. Kassai A., Illyes L., Mirdamadi H.Z., et al. The effect of atorvastatin therapy on lecithin: cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase. Clin. Biochem. 2007, 40:1-5.
162. Gouédard C., Koum-Besson N., Barouki R., Morel Y. Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. Mol. Pharmacol. 2003, 63:945-956.
163. Dullaart R.P.F., de Vries R., Voorbij H.A.M., Sluiter W.J., van Tol A. Serum paraoxonase-1 activity is unaffected by short term administration of simvastin, bezafibrate, and their combination in type 2 diabetes mellitus. Eur. J. Clin. Invest. 2009, 39:200-203.
164. Ota K., Suehiro T., Arii K., et al. Effect of pitavastatin on transactivation of human serum paraoxonase 1 gene. Metabolism 2005, 54:142-150.
165. Deakin S., Guernier S., James R.W. Pharmacogenetic interaction between paraoxonase-1 gene promoter polymorphism C-107T and statin. Pharmacogenet. Genomics 2007, 17:451-457.
166. Arii K., Suehiro T., Ota K., et al. Pitavastatin induces PON1 expression through p44/42 mitogen-activated protein kinase signaling cascade in Huh7 cells. Atherosclerosis 2009, 202:439-445.
167. Wallace A.J., Sutherland W.H., Mann J.I., Williams S.M. The effect of meals rich in thermally stressed olive and safflower oils on postprandial serum paraoxonase activity in patients with diabetes. Eur. J. Clin. Nutr. 2001, 55:951-958.
168. Tomás M., Sentí M., Elosua R., et al. Interaction between the Gln-Arg 192 variants of the paraoxonase gene and oleic acid intake as a determinant of high-density lipoprotein cholesterol and paraoxonase activity. Eur. J. Pharmacol. 2001, 432:121-128.
169. Nguyen S.D., Sok D.E. Beneficial effect of oleoylated lipids on paraoxonase 1: protection against oxidative inactivation and stabilization. Biochem. J. 2003, 375:275-285.
170. Nguyen S.D., Sok D.E. Preferential inhibition of paraoxonase activity of human paraoxonase 1 by negatively charged lipids. J. Lipid Res. 2004, 45:2211-2220.
171. Van Wijk J., Coll B., Cabezas M.C., et al. Rosiglitazone modulates fasting and post-prandial paraoxonase 1 activity in type 2 diabetic patients. Clin. Exp. Pharmacol. Physiol. 2006, 33:1134-1137.
172. Blatter-Garin M.C., Kalix B., De Pree S., James R.W. Aspirin use is associated with higher serum concentrations of the anti-oxidant enzyme, paraoxonase-1. Diabetologia 2003, 46:593-594.
173. Kurban S., Mehmetoglu I. Effects of acetylsalicylic acid on serum paraoxonase activity, Ox-LDL, coenzyme Q10 and other oxidative stress markers in healthy volunteers. Clin. Biochem. 2010, 43:287-290.
174. Marsillach J., Martínez-Vea A., Marcas L., et al. Administration of exogenous erythropoietin beta affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia. Clin. Exp. Pharmacol. Physiol. 2007, 34:347-349.
175. Jarvik G.P., Tsai N.T., McKinstry L.A., et al. Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler. Thromb. Vasc. Biol. 2002, 22:1329-1333.
176. Kunes J.P., Cordero-Koning K.S., Lee L.H., Lynch S.M. Vitamin C attenuates hypochlorite-mediated loss of paraoxonase-1 activity from human plasma. Nutr. Res. 2009, 29:114-122.
177. Sarandöl E., Taş S., Dirican M., Serdar Z. Oxidative stress and serum paraoxonase activity in experimental hypothyroidism: effect of vitamin E supplementation. Cell Biochem. Funct. 2005, 23:1-8.
178. Jeon S.M., Park Y.B., Kwon O.S., et al. Vitamin E supplementation alters HDL-cholesterol concentration and paraoxonase activity in rabbits fed high-cholesterol diet: comparison with probucol. J. Biochem. Mol. Toxicol. 2005, 19(5):336-346.
179. Boesch-Saadatmandi C., Niering J., Minihane A.M., et al. Impact of apolipoprotein E genotype and dietary quercetin on paraoxonase 1 status in apoE3 and apoE4 transgenic mice. Atherosclerosis 2010, 211(1):110-113.
180. Gouédard C., Barouki R., Morel Y. Dietary polyphenols increase paraoxonase 1 gene expression by an aryl hydrocarbon receptor-dependent mechanism. Mol. Cell. Biol. 2004, 24:5209-5222.
181. Noll C., Hamelet J., Matulewicz E., Paul J.L., Delabar J.M., Janel N. Effects of red wine polyphenolic compounds on paraoxonase-1 and lectin-like oxidized low-density lipoprotein receptor-1 in hyperhomocysteinemic mice. J. Nutr. Biochem. 2009, 20:586-596.
182. Gong M., Garige M., Varatharajalu R., et al. Quercetin up-regulates paraoxonase 1 gene expression with concomitant protection against LDL oxidation. Biochem. Biophys. Res. Commun. 2009, 379:1001-1004.
183. Boesch-Saadatmandi C., Egert S., Schrader C., et al. Effect of quercetin on paraoxonase 1 activity-studies in cultured cells, mice and humans. J. Physiol. Pharmacol. 2010, 61:99-105.
184. Kaplan M., Hayek T., Raz A., et al. Pomegranate juice supplementation to atherosclerotic mice reduces macrophage lipid peroxidation, cellular cholesterol accumulation and development of atherosclerosis. J. Nutr. 2001, 131:2082-2089.
185. Rock W., Rosenblat M., Miller-Lotan R., Levy A.P., Elias M., Aviram M. Consumption of wonderful variety pomegranate juice and extract by diabetic patients increases paraoxonase 1 association with high-density lipoprotein and stimulates its catalytic activities. J. Agric. Food Chem. 2008, 56:8704-8713.
186. Aviram M., Dornfeld L., Kaplan M., et al. Pomegranate juice flavonoids inhibit low-density lipoprotein oxidation and cardiovascular diseases: studies in atherosclerotic mice and in humans. Drugs Exp. Clin. Res. 2002, 28:49-62.
187. Khateeb J., Gantman A., Kreitenberg A.J., Aviram M., Fuhrman B. Paraoxonase 1 (PON1) expression in hepatocytes is upregulated by pomegranate polyphenols: a role for PPAR-gamma pathway. Atherosclerosis 2010, 208:119-125.
188. Fuhrman B., Volkova N., Aviram M. Pomegranate juice polyphenols increase recombinant paraoxonase-1 binding to high-density lipoprotein: studies in vitro and in diabetic patients. Nutrition 2010, 26:359-366.
189. Rosenblat M., Volkova N., Aviram M. Pomegranate juice (PJ) consumption antioxidative properties on mouse macrophages, but not PJ beneficial effects on macrophage cholesterol and triglyceride metabolism, are mediated via PJ-induced stimulation of macrophage PON2. Atherosclerosis 2010, 212:86-92.
190. Costa L.G., Vitalone A., Cole T.B., Furlong C.E. Modulation of paraoxonase (PON1) activity. Biochem. Pharmacol. 2005, 69:541-550.
191. van der Gaag M.S., van Tol A., Scheek L.M., et al. Daily moderate alcohol consumption increases serum paraoxonase activity; a diet-controlled, randomised intervention study in middle-aged men. Atherosclerosis 1999, 147:405-410.
192. Sierksma A., van der Gaag M.S., van Tol A., James R.W., Hendriks H.F. Kinetics of HDL cholesterol and paraoxonase activity in moderate alcohol consumers. Alcohol. Clin. Exp. Res. 2002, 26:1430-1435.
193. Rao M.N., Marmillot P., Gong M., et al. Light, but not heavy alcohol drinking, stimulates paraoxonase by upregulating liver mRNA in rats and humans. Metabolism 2003, 52:1287-1294.
194. Navab M., Anantharamaiah G.M., Reddy S.T., et al. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 2004, 109:3215-3220.
195. Van Lenten B.J., Wagner A.C., Jung C.L., et al. Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J. Lipid Res. 2008, 49:2302-2311.
196. Stevens R.C., Suzuki S.M., Cole T.B., Park S.S., Richter R.J., Furlong C.E. Engineered recombinant human paraoxonase 1 (rHuPON1) purified from Escherichia coli protects against organophosphate poisoning. Proc. Natl. Acad. Sci. USA. 2008, 105:12780-12784.
197. Chambers J.E. PON1 multitasks to protect health. Proc. Natl. Acad. Sci. USA. 2008, 105:12639-12640.
198. Huberts D.H., van der Klei I.J. Moonlighting proteins: an intriguing mode of multitasking. Biochim. Biophys. Acta 2010, 1803:520-525.
199. Draganov D.I. Lactonases with organophosphatase activity: structural and evolutionary perspectives. Chem. Biol. Interact. 2010, 187:370-372.
200. Jensen R.A. Enzyme recruitment in evolution of new function. Annu. Rev. Microbiol. 1974, 30:409-425.
201. Jacob F. Evolution and tinkering. Science 1977, 196:1161-1166.
202. Jacob F. Complexity and tinkering. Ann. N. Y. Acad. Sci. 2001, 929:71-73.